Talecris Files for $1 Billion IPO

Talecris Biotherapeutics Holding Corp., a Research Triangle Park, N.C.-based developer of plasma-derived protein therapies, has filed for a $1 billion IPO. It plans to trade on the Nasdaq under ticker symbol TLCR, with Morgan Stanley, Goldman Sachs and J.P. Morgan serving as co-lead underwriters. The company is controlled by Cerberus Management and Ampersand Ventures. www.talecris.com